<div class="infobox infobox-protein">
<table>
<tr><th>Protein Name</th><td><strong>DNAJB9</strong></td></tr>
<tr><th>Full Name</th><td>DnaJ heat shock protein family (Hsp40) member B9 (ERdj4)</td></tr>
<tr><th>Gene Symbol</th><td>[DNAJB9](/genes/dnajb9)</td></tr>
<tr><th>UniProt ID</th><td>[Q9Y3X0](https://www.uniprot.org/uniprot/Q9Y3X0)</td></tr>
<tr><th>Protein Family</th><td>Hsp40/DnaJ family (ER-resident)</td></tr>
<tr><th>Molecular Weight</th><td>~27 kDa</td></tr>
<tr><th>Length</th><td>223 amino acids</td></tr>
<tr><th>Subcellular Location</th><td>Endoplasmic reticulum lumen</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/age-related-diseases" style="color:#ef9a9a">Age-Related Diseases</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/carcinoma" style="color:#ef9a9a">Carcinoma</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">24 edges</a></td>
</tr>
</table>
</div>
<div class="infobox infobox-protein">
<table>
<tr><th>Protein Name</th><td><strong>DNAJB9</strong></td></tr>
<tr><th>Full Name</th><td>DnaJ heat shock protein family (Hsp40) member B9 (ERdj4)</td></tr>
<tr><th>Gene Symbol</th><td>[DNAJB9](/genes/dnajb9)</td></tr>
<tr><th>UniProt ID</th><td>[Q9Y3X0](https://www.uniprot.org/uniprot/Q9Y3X0)</td></tr>
<tr><th>Protein Family</th><td>Hsp40/DnaJ family (ER-resident)</td></tr>
<tr><th>Molecular Weight</th><td>~27 kDa</td></tr>
<tr><th>Length</th><td>223 amino acids</td></tr>
<tr><th>Subcellular Location</th><td>Endoplasmic reticulum lumen</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/age-related-diseases" style="color:#ef9a9a">Age-Related Diseases</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/carcinoma" style="color:#ef9a9a">Carcinoma</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">24 edges</a></td>
</tr>
</table>
</div>
DNAJB9 (also known as ERdj4 or Mom14) is an endoplasmic reticulum (ER)-resident co-chaperone that plays critical roles in protein folding quality control, ER-associated degradation (ERAD), and the unfolded protein response (UPR). As a member of the DnaJ/Hsp40 family of molecular chaperones, DNAJB9 facilitates the recognition and targeting of misfolded proteins for degradation, thereby protecting cells from the toxic effects of protein aggregation [1](https://pubmed.ncbi.nlm.nih.gov/18450513/).
The protein is induced during ER stress conditions and serves as a key component of the cellular protein quality control network. In the context of neurodegenerative diseases, DNAJB9 has emerged as an important protective factor whose expression is frequently dysregulated, contributing to the accumulation of misfolded proteins that characterize conditions such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis [2](https://pubmed.ncbi.nlm.nih.gov/31232541/).
DNAJB9 is a 223-amino acid protein with a characteristic domain structure that enables its chaperone functions. The protein contains several key structural features that define its role in ER protein quality control:
The N-terminal region of DNAJB9 contains a signal peptide (approximately 25 amino acids) that directs the protein to the endoplasmic reticulum. This signal peptide is cleaved during protein maturation, generating the mature protein that resides in the ER lumen [3](https://pubmed.ncbi.nlm.nih.gov/15907206/).
The central J domain is the defining feature of DnaJ/Hsp40 family proteins. This domain (approximately 70 amino acids) contains the highly conserved HPD motif and functions to stimulate the ATPase activity of Hsp70 molecular chaperones. In DNAJB9, the J domain interacts with the major ER chaperone BiP/GRP78, positioning DNAJB9 to cooperate with BiP in protein folding and ERAD substrate targeting [4](https://pubmed.ncbi.nlm.nih.gov/17631142/).
A Glycine/Phhenylalanine (G/F)-rich region follows the J domain and is thought to provide flexibility for protein-protein interactions. This region may serve as a flexible linker that allows DNAJB9 to interact with multiple client proteins and ERAD components.
The C-terminus of DNAJB9 contains the canonical KDEL sequence (Lys-Asp-Glu-Leu), which mediates retention in the endoplasmic reticulum. This retrieval signal ensures that DNAJB9 remains in the ER lumen where it performs its chaperone functions [5](https://pubmed.ncbi.nlm.nih.gov/16449189/).
DNAJB9 plays a central role in ERAD, a quality control mechanism that targets misfolded proteins from the ER for ubiquitination and degradation by the proteasome. The ERAD pathway involves recognition of misfolded proteins in the ER lumen, retrotranslocation across the ER membrane, ubiquitination in the cytoplasm, and proteasomal degradation [6](https://pubmed.ncbi.nlm.nih.gov/19131956/).
DNAJB9 contributes to ERAD through several mechanisms:
Substrate Recognition: DNAJB9 recognizes and binds to misfolded proteins that accumulate in the ER lumen. Its J domain enables recruitment of BiP/GRP78 to these substrates, facilitating proper folding or targeting for degradation.
Co-chaperone Activity: By stimulating BiP ATPase activity, DNAJB9 enhances the chaperone's ability to process ERAD substrates. This cooperation is essential for the retrotranslocation of misfolded proteins across the ER membrane.
EDEM Co-operation: DNAJB9 works in conjunction with EDEM (ER degradation-enhancing α-mannosidase-like proteins) to direct misfolded proteins to the SEL1L/HRD1 E3 ubiquitin ligase complex for degradation [7](https://pubmed.ncbi.nlm.nih.gov/22345602/).
The unfolded protein response is a collection of signaling pathways that respond to ER stress by adjusting the protein folding capacity of the cell. DNAJB9 is itself a target of the UPR, being transcriptionally upregulated by all three major UPR branches (IRE1, PERK, and ATF6) during ER stress [8](https://pubmed.ncbi.nlm.nih.gov/18606556/).
IRE1 Pathway: The IRE1 branch of the UPR splices XBP1 mRNA, generating a potent transcription factor that drives expression of DNAJB9 and other ER chaperones. XBP1 binding sites have been identified in the DNAJB9 promoter, establishing direct transcriptional regulation [9](https://pubmed.ncbi.nlm.nih.gov/14592983/).
ATF6 Pathway: The ATF6 transcription factor also contributes to DNAJB9 induction during ER stress. ATF6 is itself cleaved in response to ER stress, and the cleaved ATF6 fragment translocates to the nucleus to activate UPR target genes.
PERK Pathway: While PERK primarily mediates translational attenuation, it also contributes indirectly to DNAJB9 expression through transcriptional programs that relieve ER stress.
In Alzheimer's disease (AD), DNAJB9 expression is altered in affected brain regions. Studies have demonstrated that DNAJB9 levels are elevated in the brains of AD patients, particularly in regions with high amyloid pathology [10](https://pubmed.ncbi.nlm.nih.gov/31951684/). This upregulation likely represents a compensatory response to increased ER stress induced by amyloid-beta and tau pathology.
The neuroprotective functions of DNAJB9 in AD include:
Amyloid Processing: DNAJB9 may influence amyloid-beta production through effects on APP processing in the ER. By facilitating proper protein folding, DNAJB9 could reduce the generation of amyloidogenic fragments.
Tau Pathology: Evidence suggests that DNAJB9 can interact with tau protein and facilitate its clearance. Dysregulation of DNAJB9 in AD may contribute to the accumulation of hyperphosphorylated tau in neurofibrillary tangles.
Synaptic Protection: DNAJB9 protects against ER stress-induced synaptic dysfunction. Overexpression of DNAJB9 in neuronal cultures prevents amyloid-beta-induced synaptic protein loss and dendritic spine reduction [11](https://pubmed.ncbi.nlm.nih.gov/32040176/).
Parkinson's disease (PD) is characterized by the accumulation of alpha-synuclein in Lewy bodies. DNAJB9 has been shown to interact with alpha-synuclein and facilitate its clearance through ERAD pathways [12](https://pubmed.ncbi.nlm.nih.gov/29154815/).
In PD models:
Amyotrophic lateral sclerosis (ALS) involves progressive motor neuron degeneration driven by protein aggregation. DNAJB9 is upregulated in ALS motor neurons and may play protective roles by facilitating clearance of misfolded SOD1, TDP-43, and FUS proteins [13](https://pubmed.ncbi.nlm.nih.gov/29953852/).
The ER stress response is prominently activated in ALS, with elevated markers of UPR activation observed in post-mortem spinal cord tissue. DNAJB9 induction represents one component of this protective response, though the response is ultimately insufficient to prevent disease progression.
DNAJB9 dysregulation has been implicated in several additional neurodegenerative conditions:
Huntington's Disease: DNAJB9 interacts with mutant huntingtin protein and may facilitate its clearance. Expression is altered in HD models and patient tissue.
Prion Diseases: The accumulation of misfolded prion protein triggers ER stress and DNAJB9 upregulation. This response may influence disease progression.
Multiple Sclerosis: DNAJB9 expression is altered in demyelinating diseases, potentially reflecting ER stress in oligodendrocytes.
DNAJB9 participates in a network of protein interactions relevant to neurodegeneration:
The protective role of DNAJB9 in neurodegenerative diseases has prompted interest in developing therapeutic strategies that enhance its function:
Small Molecule Inducers: Compounds that upregulate DNAJB9 expression could enhance ER quality control capacity. Examples include ER stress-independent inducers that avoid the detrimental effects of chronic UPR activation.
Protein Stabilization: Developing compounds that stabilize DNAJB9 protein or enhance its interaction with Hsp70 partners could boost its chaperone activity.
Gene Therapy: Viral vector-mediated delivery of DNAJB9 to affected brain regions represents a potential approach, though delivery challenges and safety concerns must be addressed.
Combination Approaches: Targeting DNAJB9 alongside other components of the ER quality control network may provide synergistic benefits.
DNAJB9 is an ER-resident co-chaperone that plays essential roles in protein quality control through its involvement in ERAD and the UPR. Its ability to recognize misfolded proteins and facilitate their degradation makes it an important protective factor in neurodegenerative diseases characterized by protein aggregation. The induction of DNAJB9 during ER stress represents a compensatory response that is often insufficient in chronic neurodegenerative conditions. Understanding and enhancing DNAJB9 function represents a promising therapeutic avenue for treating diseases including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis.